Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipation Treatment Market: Critical Driver Shaping the Opioid-Induced Constipation Treatment Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.0%. This notable development in the historic timeframe is primarily due to factors such as burgeoning population of elderly individuals, tailor-made OIC therapies, access to successful OIC medications, increasing incidence of opioid consumption, and a growing number of gastrointestinal disorder cases.

Opioid-Induced Constipation Treatment Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the market size for treatments of opioid-induced constipation is anticipated to experience substantial growth. The market is predicted to reach $2.47 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this projected growth during the forecast period include quicker approval processes for drugs, growing usage of opioid analgesics prescriptions, mounting spend on research and development for new treatments, and a rise in the creation of biologics. Key trends for the forecast period encompass educating and raising awareness among patients, the advent of targeted therapies, interventions that are non-pharmacological, innovations in biotechnology, and heightened investment.

View the full report here:
https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are the Drivers Transforming the Opioid-Induced Constipation Treatment Market?
An increase in the usage of opioids for treating cancer and non-cancer associated pain is likely to spur the expansion of the market for opioid-induced constipation therapy. The pain relating to cancer and its treatment is known as cancer pain, while non-cancer pain is pain arising from non-cancerous conditions. The administration of opioids for these types of pain is motivated by the need for effective management of moderate to severe pain. This takes into account aspects like the severity and duration of the pain, the patient's reaction to alternate treatments, and the overall aim of enhancing the quality of life, while at the same time mitigating the possible dangers of addiction and side effects. Opioid-induced constipation (OIC) therapy aids patients dealing with cancer and non-cancer pain by mitigating constipation resulting from opioid usage. This in turn enhances their overall comfort, adherence to pain management schemes, and quality of life without affecting pain alleviation. For example, as per the Government of Canada in May 2021, it is anticipated that by 2025, around 8.3 million Canadians could be dealing with chronic pain, and this number is projected to rise to up to 9.0 million by 2030. Hence, the escalated use of opioids for cancer and non-cancer pain is fueling the growth of the market for opioid-induced constipation treatment.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

What Long-Term Trends Will Define the Future of the Opioid-Induced Constipation Treatment Market?
Key players in the opioid-induced constipation treatment market are strategically partnering to foster the creation of innovative medications. Such strategic alliances allow opioid-induced constipation treatment enterprises to pool resources and knowledge, boost research and development efforts, extend their market influence, and expedite product commercialization, thereby sparking innovation and growth in the industry. To illustrate, in November 2022, Japan's Kyowa Kirin Co. Ltd, a biotechnology firm, joined forces with Grünenthal GmbH, a pharmaceutical company based in Germany to consolidate their patient care solutions. The collaboration aims to stimulate the development and worldwide accessibility of a range of transformative pain management treatments, including therapies for opioid-induced constipation, breakthrough cancer pain, and osteoporosis.

Which Segments in the Opioid-Induced Constipation Treatment Market Offer the Most Profit Potential?
The opioid-induced constipation treatment market covered in this report is segmented -

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Which Firms Dominate the Opioid-Induced Constipation Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

Which Regions Offer the Highest Growth Potential in the Opioid-Induced Constipation Treatment Market?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.